Apremilast in refractory orogenital ulcers and other manifestations of Behcet's disease. A national multicentre study of 51 cases in clinical practice

Autor: Atienza-Mateo B, Martín-Varillas JL, Graña J, Espinosa G, Moriano C, Pérez-Sandoval T, García-Armario MD, Castellví I, Román-Ivorra JA, Olivé A, Ybáñez A, Martinez-Ferrer A, Narváez J, Romero-Yuste S, Ojeda S, Ros I, Loricera J, Calvo-Río V, Castañeda S, Gonzalez-Gay MA, Blanco R, Spanish Collaborative Group of Refractory Behçet's Disease

Publikováno v: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

Objective. The objective of the present study was to assess the efficacy of apremilast (APR) in the management of refractory oral and/or genital ulcers in patients with Behcet's disease (BD). Methods. National multicentre openlabel observational stud

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::45341e1d2fa0bd835613bf5f428f539c
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=9300